Evidence map›Paper›PMID 41982701›Full record

ArticleTranslational lung cancer research2026

Molecular and clinical disparity of

Dayoung Yoon, Ji Won Lee, Byoung Chul Cho, Eun Joo Kang, Jung Sun Kim, Taekyu Lim, Seong Yoon Yi, Yu Jung Kim, Mi Sun Ahn, Young Saing Kim and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Dayoung YoonDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Ji Won LeeDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Byoung Chul ChoDivision of Medical Oncology, Yonsei Cancer Center, Seoul, Korea.
Eun Joo KangDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Jung Sun KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
Taekyu LimDivision of Hematology-Oncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Korea.
Seong Yoon YiDivision of Hematology-Oncology, Department of Internal Medicine, Inje University Ilsan Hospital, Goyang, Korea.
Yu Jung KimDepartment of Internal Medicine, Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Mi Sun AhnAjou University Medical Center, Suwon, Korea.
Young Saing KimDivision of Medical Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Ji Hyun ParkDepartment of Hemato-Oncology, Konkuk Medical Center, University of Konkuk College of Medicine, Seoul, Korea.
Seungtaek LimDepartment of Oncology, Wonju Severance Christianity Hospital, Wonju-si, Korea.
Hyung Soon ParkDivision of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Jang Ho ChoDivision of Oncology, Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Byunghyun JangDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Ji Yoon LeeDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Jiwon KimDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Jisoo HongoncoMASTER Inc., Seoul, Korea.
Harim KooDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Seok ChungKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Korea.
Sang Won ShinDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Yeul Hong KimDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Jason K SaDepartment of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Yoon Ji ChoiDivision of Hematology-Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a cornerstone of therapy for advanced Methods: We have collected and profiled the complex genomes of 121 ES and 74 AS NSCLCs to determine their molecular and clinical disparities. Furthermore, we analyzed 84 Results: In the study, significant enrichment of mutations in Conclusions: Given the growing importance of biomarker-driven treatment in the field of oncology, our results collectively open up new therapeutic opportunities for ES NSCLC patients.

Indexed as

epidermal growth factor receptor mutations (EGFR mutations)Non-small cell lung cancer (NSCLC)stageTKI resistancetyrosine kinase inhibitor-treatments (TKI-treatments)

Identifiers

PMID41982701
PMCPMC13071744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.